Seqens, with more than 30 years-experience in the pharma industry, are the undisputed Europe-based CDMO leader in the Small molecule Drug substance space.
Seqens are a partner of choice for more than 1,000 customers around the world backed by the highest level of service and commitment thanks to strong CMC project management team while acting ethically in accordance with a strong Environmental, Social and Governance program.

State-of-the-art R&D facilities (in Europe and in the US) and an extensive network of 10 Western manufacturing sites (both GMP and nonGMP) permit Seqens to offer the widest range of solutions to innovative pharmas.
Seqens support their customer from the very early stage of the development of their assets until commercial production:
- Preclinical R&D work (route scouting, non GMP tox batches…)
- Process and analytical development, QBD, kilo-lab and pilot production
- cGMP clinical supply
- nonGMP / GMP intermediates, RSMs and APIs manufacturing
- Standalone analytics (Nitrosamines quantification, solid state studies…)
- Pre-formulation work